Monsanto and Bayer Announce Approval of Massive Merger

On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, LARS PLOUGHMANNIn a move that has been anticipated for months, agribusiness corporation Monsanto has taken another step towards finalizing a $66 billion merger with Bayer AG, the Germany-based pharma and chemical firm. On Tuesday (December 13) Monsanto’s shareholders overwhelmingly approved the $128 per share price paid by Bayer for the acquisition. The new entity will represent the world’s largest agriculture and chemical company.

“This is a really significant milestone,” Monsanto CEO Hugh Grant told the St. Louis Post-Dispatch. “When you get 99 percent affirmation, that's very encouraging.”

But outside of the 99 percent of Monsanto shareholders who approved the deal, one individual filed a lawsuit to stop it, alleging that the shares were worth more than $128 a piece. That suit was thrown out by a St. Louis County judge.

The National Farmers Union has also spoken out against the deal. “Consolidation of this magnitude cannot be the standard for agriculture, nor should we allow it to determine the landscape for our future,” the organization said in a statement posted in September, when the merger was first announced. The Natural Resources Defense Council (NRDC) sent a letter on ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
A greyscale image of cells dividing.
March 2025, Issue 1

How Do Embryos Know How Fast to Develop

In mammals, intracellular clocks begin to tick within days of fertilization.

View this Issue
Discover the history, mechanics, and potential of PCR.

Become a PCR Pro

Integra Logo
Explore polypharmacology’s beneficial role in target-based drug discovery

Embracing Polypharmacology for Multipurpose Drug Targeting

Fortis Life Sciences
3D rendered cross section of influenza viruses, showing surface proteins on the outside and single stranded RNA inside the virus

Genetic Insights Break Infectious Pathogen Barriers

Thermo Fisher Logo
A photo of sample storage boxes in an ultra-low temperature freezer.

Navigating Cold Storage Solutions

PHCbi logo 

Products

BIOVECTRA

BIOVECTRA is Honored with 2025 CDMO Leadership Award for Biologics

Sino Logo

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV

Stirling Ultracold

Meet the Upright ULT Built for Faster Recovery - Stirling VAULT100™

Stirling Ultracold logo
Chemidoc

ChemiDoc Go Imaging System ​

Bio-Rad